Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine
Approval granted by South Korea's Ministry of Food and Drug Safety (MFDS) Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for the preventive treatment of migraine in adults Authorization supported by the Phase 3 SUNRISE trial conducted in a predominantly Asian population with chronic migraine Provides a new preventive treatment option for people living with migraine...
“The Era of Cuffless is Here”… Ring-Type Blood Pressure Monitor ‘CART BP pro’ Becomes World’s First to Be Integrated into Official Hypertension Guidelines
SEOUL, South Korea, May 26, 2026 /PRNewswire/ -- Sky Labs (CEO Jack ByungHwan Lee) announced on the 26th that its ring-type cuffless blood pressure monitor, 'CART BP pro,' has been officially integrated into the '2026 Korean Society of Hypertension Guidelines for the Management of Hypertension (6th Edition).' The official guideline slide previewed...
Global Times: How mutual commitment of Xizang and medical aid workers improves local healthcare
BEIJING, May 26, 2026 /PRNewswire/ -- National support for Xizang's development has yielded remarkable achievements. Over the decades, numerous volunteers from across the country have come to Xizang, making indispensable contributions to the autonomous region's growth. Their efforts focus on various fields such as education, healthcare and infrastructure. Despite harsh conditions, these volunteers persevere in their roles, writing chapters...
Over 40 Studies Featuring Akeso’s Innovative Oncology Agents to Be Presented at ASCO 2026: Ivonescimab’s HARMONi-6 Overall Survival Data Selected for Plenary Session
HONG KONG, May 26, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that more than 40 clinical studies of its oncology portfolio will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 – June 2 in Chicago, Illinois. Notably, the presentations include one Late-Breaking Abstract (LBA) selected for...
WuXi Vaccines’ Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
SUZHOU, China, May 26, 2026 /PRNewswire/ -- WuXi Vaccines, a wholly-owned subsidiary of WuXi Biologics, dedicated to vaccine Contract Development and Manufacturing Organization (CDMO), announced today that its drug substance facility (MFG23) located in Suzhou has received Good Manufacturing Practices (GMP) certification from Brazil's Agência Nacional de Vigilância Sanitária (ANVISA). The facility is providing integrated manufacturing services for Instituto...
Yili Unveils Global Innovation Vanguard Initiative in Cambridge, UK
CAMBRIDGE, England, May 26, 2026 /PRNewswire/ -- Recently, Yili Group hosted the launch of its Global Innovation Vanguard Initiative in Cambridge, UK. Under the theme "Gathering Global Wisdom, Pioneering a Healthier Future," the event marked the debut of a comprehensive, open-access R&D framework designed to elevate the dairy value chain. To advance this mission, Yili signed agreements with Springer...
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant...
This positive CHMP opinion is based on results from the Phase 3 BREAKWATER trial, which showed that encorafenib in combination with cetuximab and mFOLFOX6 demonstrated a statistically significant improvement in the dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS), and a significant overall survival (OS) benefit, reducing the...
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
Data spans seven presentations across both solid tumors and hematologic malignancies, providing updates on the potential benefit these therapies may bring to patients. Data from the elacestrant plus capivasertib regimen of the ELEVATE study will be presented underscoring its potential in combination settings in mBC, along with updates from the elacestrant clinical...
sweelin® Approved in Singapore as a Food Additive expanding Amai Proteins’ Regulatory Footprint into Asia
Amai Proteins has achieved a major regulatory milestone with the Singapore Food Agency (SFA) approval of sweelin®, its flagship sweet protein, for use as a sweetening agent in food and beverage products. sweelin® is a next-generation sweet protein that enables significant sugar reduction and replaces conventional sweeteners with a protein-based alternative, designed to deliver superior clean taste, competitive cost,...
THE FUTURE OF MEN’S HEALTH IS MEASURABLE: EMAGENE.LIFE AND ADAM HEALTH PARTNER TO ADVANCE PRECISION LONGEVITY AND FUNCTIONAL MEDICINE
Emagene.life integrates advanced biodata intelligence, functional medicine, and Avio Health AI technology through a strategic collaboration with Adam Health to support measurable male vitality and longevity. KUALA LUMPUR, Malaysia, May 25, 2026 /PRNewswire/ -- Men's health is entering a new era of measurable, AI-informed precision care as Emagene.life announces a strategic partnership with Adam Health to advance functional medicine,...
